vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $11.1M, roughly 1.9× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -66.3%, a 283.0% gap on every dollar of revenue. On growth, Pulmonx Corp posted the faster year-over-year revenue change (-8.7% vs -48.8%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.

LUNG vs NREF — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.9× larger
LUNG
$20.6M
$11.1M
NREF
Growing faster (revenue YoY)
LUNG
LUNG
+40.2% gap
LUNG
-8.7%
-48.8%
NREF
Higher net margin
NREF
NREF
283.0% more per $
NREF
216.6%
-66.3%
LUNG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
NREF
NREF
Revenue
$20.6M
$11.1M
Net Profit
$-13.7M
$24.0M
Gross Margin
77.9%
Operating Margin
-40.9%
Net Margin
-66.3%
216.6%
Revenue YoY
-8.7%
-48.8%
Net Profit YoY
5.5%
58.7%
EPS (diluted)
$-0.33
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
NREF
NREF
Q1 26
$20.6M
Q4 25
$22.6M
$11.1M
Q3 25
$21.5M
$12.5M
Q2 25
$23.9M
$12.1M
Q1 25
$22.5M
$11.5M
Q4 24
$23.8M
$21.7M
Q3 24
$20.4M
$12.5M
Q2 24
$20.8M
$6.7M
Net Profit
LUNG
LUNG
NREF
NREF
Q1 26
$-13.7M
Q4 25
$-10.4M
$24.0M
Q3 25
$-14.0M
$50.9M
Q2 25
$-15.2M
$22.3M
Q1 25
$-14.4M
$26.0M
Q4 24
$-13.2M
$15.2M
Q3 24
$-14.1M
$23.3M
Q2 24
$-15.3M
$12.1M
Gross Margin
LUNG
LUNG
NREF
NREF
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
LUNG
LUNG
NREF
NREF
Q1 26
-40.9%
Q4 25
-43.8%
Q3 25
-66.9%
Q2 25
-62.0%
Q1 25
-64.6%
Q4 24
-56.5%
Q3 24
-69.3%
Q2 24
-75.2%
Net Margin
LUNG
LUNG
NREF
NREF
Q1 26
-66.3%
Q4 25
-46.1%
216.6%
Q3 25
-64.9%
407.0%
Q2 25
-63.6%
184.5%
Q1 25
-64.1%
225.6%
Q4 24
-55.4%
69.9%
Q3 24
-69.4%
186.4%
Q2 24
-73.7%
179.7%
EPS (diluted)
LUNG
LUNG
NREF
NREF
Q1 26
$-0.33
Q4 25
$-0.25
$0.47
Q3 25
$-0.34
$1.14
Q2 25
$-0.38
$0.54
Q1 25
$-0.36
$0.70
Q4 24
$-0.33
$0.71
Q3 24
$-0.36
$0.74
Q2 24
$-0.39
$0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
NREF
NREF
Cash + ST InvestmentsLiquidity on hand
$61.6M
$31.1M
Total DebtLower is stronger
$37.3M
$771.2M
Stockholders' EquityBook value
$45.8M
$388.0M
Total Assets
$120.0M
$5.3B
Debt / EquityLower = less leverage
0.82×
1.99×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
NREF
NREF
Q1 26
$61.6M
Q4 25
$69.8M
$31.1M
Q3 25
$76.5M
$17.9M
Q2 25
$75.5M
$9.1M
Q1 25
$74.6M
$19.2M
Q4 24
$70.9M
$3.9M
Q3 24
$63.3M
$34.7M
Q2 24
$63.5M
$4.3M
Total Debt
LUNG
LUNG
NREF
NREF
Q1 26
$37.3M
Q4 25
$37.1M
$771.2M
Q3 25
$37.1M
$720.9M
Q2 25
$37.1M
$815.6M
Q1 25
$37.2M
$831.5M
Q4 24
$37.2M
$799.3M
Q3 24
$37.2M
$815.5M
Q2 24
$37.2M
$861.0M
Stockholders' Equity
LUNG
LUNG
NREF
NREF
Q1 26
$45.8M
Q4 25
$54.1M
$388.0M
Q3 25
$60.0M
$375.4M
Q2 25
$69.1M
$348.2M
Q1 25
$77.7M
$343.7M
Q4 24
$85.8M
$336.5M
Q3 24
$93.9M
$335.8M
Q2 24
$101.2M
$327.5M
Total Assets
LUNG
LUNG
NREF
NREF
Q1 26
$120.0M
Q4 25
$129.3M
$5.3B
Q3 25
$138.3M
$5.3B
Q2 25
$147.2M
$5.4B
Q1 25
$150.7M
$5.4B
Q4 24
$162.8M
$5.4B
Q3 24
$167.4M
$5.7B
Q2 24
$172.6M
$6.6B
Debt / Equity
LUNG
LUNG
NREF
NREF
Q1 26
0.82×
Q4 25
0.69×
1.99×
Q3 25
0.62×
1.92×
Q2 25
0.54×
2.34×
Q1 25
0.48×
2.42×
Q4 24
0.43×
2.38×
Q3 24
0.40×
2.43×
Q2 24
0.37×
2.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
NREF
NREF
Operating Cash FlowLast quarter
$-4.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
NREF
NREF
Q1 26
Q4 25
$-7.1M
$-4.5M
Q3 25
$-8.2M
$8.1M
Q2 25
$-3.9M
$3.3M
Q1 25
$-13.2M
$16.0M
Q4 24
$-6.7M
$4.4M
Q3 24
$-7.2M
$14.7M
Q2 24
$-5.8M
$-7.5M
Free Cash Flow
LUNG
LUNG
NREF
NREF
Q1 26
Q4 25
$-7.1M
Q3 25
$-8.3M
Q2 25
$-4.0M
Q1 25
$-13.5M
Q4 24
$-6.8M
Q3 24
$-7.7M
Q2 24
$-6.2M
FCF Margin
LUNG
LUNG
NREF
NREF
Q1 26
Q4 25
-31.4%
Q3 25
-38.4%
Q2 25
-16.6%
Q1 25
-60.0%
Q4 24
-28.8%
Q3 24
-37.6%
Q2 24
-30.0%
Capex Intensity
LUNG
LUNG
NREF
NREF
Q1 26
Q4 25
0.1%
Q3 25
0.4%
Q2 25
0.2%
Q1 25
1.3%
Q4 24
0.5%
Q3 24
2.0%
Q2 24
2.3%
Cash Conversion
LUNG
LUNG
NREF
NREF
Q1 26
Q4 25
-0.19×
Q3 25
0.16×
Q2 25
0.15×
Q1 25
0.62×
Q4 24
0.29×
Q3 24
0.63×
Q2 24
-0.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons